



PRESS RELEASE

Alpha IVF Group sets up new record: Highest number of consecutive embryos that survived the freeze-thaw process - 10,290 Embryos Achieve 100.00% Post-Thaw Survival Rate.

- *Breakthrough boosts patient confidence, supports expansion plans across Southeast Asia and booming Chinese fertility sector*
- *Malaysia Book of Records acknowledges historic achievement*

KUALA LUMPUR, Malaysia, 13 August 2024 - Leading fertility care specialist, Alpha IVF Group Berhad (“Alpha IVF Group”, “the Group”, “阿儿法国际辅助生殖集团”, Bloomberg: ALPHA MK, Bursa Ticker: 0303) announced a groundbreaking achievement in the field of reproductive medicine, attaining an unprecedented 100.00% post-thaw survival rate for consecutive 10,290 blastocysts and embryos, key developmental stages of a fertilized egg used in-vitro fertilization (IVF).

The accomplishment, recognized by the Malaysia Book of Records, potentially sets a new global standard and underscores the success of the Group’s regional expansion plans. The survival of frozen-thawed blastocysts and embryos is critical to successful pregnancy outcomes, and its achievement of 100.00% post-thaw survival rate demonstrates its leadership in assisted reproductive technology (ART) and commitment to excellence across its entire integrated ART protocols.

Receiving the Malaysia Book of Records on behalf of Alpha IVF Group, Group Managing Director Dato’ Dr. Colin Lee Soon Soo said that the achievement is a significant industry milestone that boosts patient confidence and serves as a catalyst for the Group’s ambitious growth strategy.

“This breakthrough achievement reinforces our commitment to providing the highest quality fertility treatments and supports our ambitious expansion plans, enabling us to help even more individuals and couples achieve their dreams of parenthood.

We are actively expanding our footprint in Southeast Asia and exploring opportunities in the growing Chinese market. Our vision is a future where advanced fertility treatments are accessible to all, and we are dedicated to leading the industry in achieving optimal success rate. This achievement not only transforms lives but also drives Alpha IVF Group’s substantial growth.”

Dato’ Dr Colin Lee Soon Soo (拿督 李顺树医生)
Group Managing Director, Alpha IVF Group

Alpha IVF Group is actively expanding its footprint in Southeast Asia. The Group’s recently launched fourth specialist centre in Kuala Lumpur, Alhaya Fertility Centre, is already experiencing increased patient volumes. The Group is also pursuing further expansion in Southeast Asia, including plans to establish new satellite clinics in Indonesia, to increase access to its world-class fertility services.



Furthermore, the Group is strategically targeting the rapidly growing Chinese fertility market, where it is witnessing a surge in patients seeking treatment at its Malaysian facilities. To further capitalize on this opportunity, Alpha IVF Group is establishing sales and marketing offices and forging strategic partnerships in China.

Alpha IVF Group has demonstrated significant growth in its quarterly profit performance and year-on-year improvements in the financial year 2024, driven by increasing patient arrivals from both international and domestic markets. Building on this momentum, the Group is poised for an even more successful year ahead.

Dato' Dr Colin Lee added, "Our strong financial performance and the increasing demand for our services validate our expansion strategy. We are committed to increasing our regional reach and providing the highest quality fertility treatments to more patients."



About Alpha IVF Group Berhad (“Alpha IVF Group”)

Alpha IVF Group is one of the largest fertility care specialists, currently operating in Malaysia and Singapore. The group primarily focuses on Assisted Reproductive Services (ARS), with a strong emphasis on In-vitro Fertilisation (IVF). Presently, the group operates three specialist centres in Malaysia - Alpha International Women’s Specialists Sdn Bhd (“Alpha KL”), Alhaya International Women’s Specialists Sdn Bhd (“Alhaya”) in Kuala Lumpur, and Genesis Specialists Sdn Bhd (“Genesis”) in Penang - and one in Singapore, known as Alpha International Women’s Specialists (Singapore) Pte Ltd (“Alpha Singapore”).

In addition to IVF, Alpha IVF Group provides various assisted reproductive procedures, including intracytoplasmic sperm injection, intrauterine insemination, diagnostics, testing, screening procedures, and Cyrotec® cryopreservation of eggs, sperm, and embryos.

Since its inception in 2011, Alpha IVF Group has earned a strong reputation with a branding synonymous with exceptional success rates among regional peers in IVF. The high pregnancy rates are attributed to the Group’s robust foundation, known as the “System of Systems,” and its five strategic pillars: leading medical specialists, highly skilled embryologists, continuous research and development, innovative techniques, and cutting-edge laboratory equipment.

Alpha IVF Group’s operations have provided IVF services to international patients hailing from Indonesia, China, Singapore, the Middle East, and various other countries. The Group has also pioneered numerous innovations leading to improved pregnancy rates and is actively involved in utilising advanced Artificial Intelligence technology to enhance embryo selection for higher IVF success rates.

Alpha IVF Group was recognised by Newsweek magazine as the Leading Fertility Centre in Asia 2024 and by Healthcare Asia, with Alpha IVF Group Berhad securing the Technology Innovation of the Year Award - Malaysia. These accolades underscore the Group’s commitment to research and development, as well as its innovative use of advanced technologies.

Issued for and on behalf of ALPHA IVF GROUP BERHAD by Aquilas Advisory (Malaysia) Sdn Bhd. For media enquiries, please contact:

Ms. Azja Delana

azja@aquilas.com.my

T: 03-2711 1391 / 019-5886 088